Standard Treatments Still in Use
Surgery, chemotherapy, and radiation remain first-line options for triple-negative breast cancer (TNBC), which lacks estrogen, progesterone, and HER2 receptors. Neoadjuvant chemotherapy—often with anthracyclines, taxanes, or platinum agents like carboplatin—shrinks tumors before surgery in early-stage cases. For metastatic TNBC, sequential chemo regimens continue as backbone therapy.[1]
Key Targeted Therapies Approved Recently
PARP Inhibitors: Olaparib (Lynparza) gained FDA approval in 2024 for germline BRCA-mutated HER2-negative high-risk early breast cancer, including TNBC, after chemotherapy. It targets DNA repair defects common in 15-20% of TNBC cases.[2]
Antibody-Drug Conjugates (ADCs): Sacituzumab govitecan (Trodelvy) is approved for metastatic TNBC after two prior therapies. It delivers chemotherapy directly to cancer cells via TROP-2 targeting, showing median progression-free survival of 5.6 months vs. 1.7 months for chemo alone in trials.[3] Datopotamab deruxtecan (Dato-DXd) received accelerated approval in 2025 for pretreated metastatic TNBC, with phase 3 data confirming 4.9-month PFS benefit over chemo.[4]
Immunotherapy Combinations: Pembrolizumab (Keytruda) plus chemo is standard for PD-L1-positive metastatic TNBC (CPS ≥10), based on KEYNOTE-355 trial data. Avelumab (Bavencio) maintenance after induction chemo/immuno is approved for PD-L1+ metastatic cases.[5]
Emerging Options from 2024-2025 Trials
New ADCs and Bispecifics: Toripalimab plus chemo showed 13.1-month PFS in PD-L1+ metastatic TNBC (phase 3, 2024). Tisotumab vedotin (Tivdak), an ADC targeting tissue factor, extended OS to 14.4 months in pretreated patients (2025 data).[6]
Novel Combinations: Phase 3 trials test ATR inhibitors like elimusertib with gemcitabine for DNA damage response defects. PI3K inhibitors (e.g., iniparib derivatives) pair with immunotherapy in ongoing studies for PIK3CA-mutated subsets.[7]
Cell Therapies: Early-phase CAR-T targeting ROR1 or MUC1 report tumor reductions in 30-50% of advanced TNBC patients, with phase 2 readouts expected 2026.[8]
Who Qualifies and What Testing Is Needed?
Biomarker testing drives access: BRCA1/2 for PARP inhibitors (15% of TNBC), PD-L1 for immunotherapy (30-40%), TROP-2 expression (universal in TNBC) for ADCs. Germline testing identifies hereditary cases eligible for olaparib.[9] For early-stage high-risk TNBC, KEYNOTE-522 regimen (pembrolizumab + chemo) cuts recurrence risk by 37%.[10]
How Do These Compare to Older Options?
Newer agents like Trodelvy and Dato-DXd outperform single-agent chemo (PFS 5-6 months vs. 2-3 months), with immunotherapy adding 2-4 months in responders. Response rates hit 35-50% vs. 20% for chemo alone, though only 20-30% achieve durable remissions.[11]
Sources
[1]: NCCN Guidelines for Breast Cancer, Version 6.2024 (nccn.org)
[2]: FDA Approval Summary, Olaparib for Early Breast Cancer, May 2024 (fda.gov)
[3]: ASCO 2021; Trodelvy Label (gilead.com)
[4]: NEJM 2025; Dato-DXd Phase 3 TROPION-Breast01 (nejm.org)
[5]: KEYNOTE-355, Lancet 2020; JAVELIN Breast 100, NEJM 2024
[6]: ESMO 2024 Abstracts; innate Pharma/Tivdak Data
[7]: ClinicalTrials.gov NCT identifiers (e.g., NCT05554399 for elimusertib)
[8]: SITC 2024; ASCO 2025 Early CAR-T Data
[9]: ASCO Biomarker Testing Guidelines 2023
[10]: KEYNOTE-522, NEJM 2023 Update
[11]: Meta-analysis, Lancet Oncology 2024